A trial to learn how safe AZD0022 is, how well it works, and how it moves throughout the body over time in adults with tumors that have a KRAS-G12D mutation, when given alone and with other cancer drugs

Phase 1/2

Recruiting

• Conditions: Non Small Cell Lung Cancer Colorectal Cancer Pancreatic Ductal Adenocarcinoma

• Registration Number: 2024-516699-14-00
• Lead Sponsor: AstraZeneca AB

Brief Summary

For Parts A and B: To investigate the safety and tolerability, determine the MTD and/or OBD of AZD0022 as a monotherapy and in combination with other anti-cancer agents in participants with advanced tumours harbouring a KRASG12D mutation.

For Part C: To assess the anti-tumour activity of AZD0022 as a monotherapy and in combination with other anti-cancer agents

Detailed Description

This first time in human, open-label, multi-centre study will administer AZD0022 orally to participants with tumours harbouring a KRASG12D mutation.

This study will have initially 2 modules.

* Module 1: AZD0022 monotherapy

* Module 2: AZD0022 in combination with other anti-cancer agents (Cetuximab)

Each Module has 3 parts. Dose Escalation (Part A), Dose Optimisation (Part B) and Potential Efficacy Expansion (Part C).

Study Timeline

• Study First Submitted: 2024-08-19
• Study First Submitted QC: 2024-09-13
• Study First Posted: 2024-09-19
• Study Start: 2024-10-18
• Status Verified: 2025-10
• Last Update Submitted: 2025-10-09
• Last Update Posted: 2025-10-10
• Primary Completion: 2028-01-20
• Study Completion: 2028-01-20

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 126

Inclusion Criteria

For whole study:

1. Participant must be ≥ 18 years or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the ICF.
2. Participants must have a histologically or cytologically confirmed metastatic or locally advanced tumour. Further details on tumour types are specified in Module-specific inclusion criteria.
3. Participants must have received and progressed on, are refractory or are intolerant to standard therapy for the specific tumour type, or as per Module-specific criteria. Participants with contraindications to, or who refuse SoC therapy may be considered, provided that it is documented and the participant has been informed about all available therapeutic options.
4. Documented KRASG12D mutation in tissue or liquid biopsy.
5. Provision of a FFPE tumour sample.
6. Participants must have at least one measurable target lesion per RECIST v1.1.
7. Adequate organ and marrow function as defined in study protocol.

Module 1 Key Inclusion Criteria

1. Type of tumours with a KRASG12D mutation:

   1. For NSCLC: Patients must have NSCLC that is not amenable to curative treatment and should have progressed on at least one prior line of SoC treatment for metastatic NSCLC (including but not limited to platinum-based chemotherapy, immunotherapy, targeted therapy or first line SoC combinations); prior experimental treatments are allowed.
   2. For CRC: Patients must have CRC that is not amenable to curative treatment and should have progressed on at least 2 prior lines of SoC treatment for metastatic CRC; prior experimental treatments are allowed.
   3. For PDAC: Patients must have PDAC that is not amenable to curative treatment and should have progressed at least one prior line of SoC treatment for metastatic PDAC (including but not limited to FOLFIRINOX, gemcitabine plus abraxane and gemcitabine monotherapy); prior experimental treatments are allowed.
   4. For patients enrolled in Part C (NSCLC and PDAC): at least one but no more than 2 lines of prior treatment in metastatic settings; prior experimental treatments are allowed.

2. Progression or recurrence of the disease within 6 months of completing neo/adjuvant treatment (ie, chemotherapy, immunotherapy, chemoradiotherapy, etc) will be considered as a first line of treatment.

3. For Part B food-effect cohort, participants must be able to eat a standard high-fat meal and must be able to fast for at least 10 hours.

Module 2 Inclusion Criteria

1. For Part A (M2A, dose escalation) participants must have pathologically documented locally advanced or metastatic CRC with a KRASG12D mutation.
2. For Part B (M2B, dose optimisation) participants must have pathologically documented locally advanced or metastatic, PDAC or CRC with a KRASG12D mutation.
3. For Part C (M2C, potential efficacy expansion) participants must have pathologically documented locally advanced or metastatic CRC with a KRASG12D mutation.

4(a) For CRC: Patients must have CRC that is not amenable to curative treatment and should have progressed on at least 2 prior lines of SoC treatment for metastatic CRC; prior treatment are allowed.

(b) For PDAC: Patients must have PDAC that is not amenable to curative treatment and should have progressed at least one prior line of SoC treatment for metastatic PDAC (including but not limited to FOLFIRINOX, gemcitabine plus abraxane and gemcitabine monotherapy); prior experimental treatment are allowed.

(c) For patients enrolled in Part C (M2C), at least 2 but no more than 3 lines of prior treatment in metastatic setting; prior experimental treatment are allowed.

5. Progression or recurrence of the disease within 6 months of completing neo/adjuvant treatment (ie, chemotherapy, immunotherapy, and chemoradiotherapy) will be considered as a first line of treatment.

Exclusion Criteria

For whole study:

1. Any significant laboratory finding or any severe and uncontrolled medical condition.

2. Any evidence of clinically significant current or prior ILD (eg, required IV steroids or high supplemental oxygen) or where a new suspected ILD cannot be ruled out by imaging at screening.

3. Spinal cord compression, leptomeningeal disease, or active brain metastases. Asymptomatic brain metastases are allowed

4. History of allogenic organ transplantation.

5. Participants with any of the following cardiac criteria:

   • Mean resting QTcF > 470 milliseconds on screening
   • Any factors that increase the risk of QT prolongation
   • Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (eg, complete left bundle branch block, second- or third-degree atrioventricular block), and clinically significant sinus node dysfunction not treated with pacemaker.
   • Bradycardia defined as a heart rate less than 60 beats per minute and/or hypotension defined as a blood pressure reading lower than 90 mm Hg for the top number (systolic) or 60 mm Hg for the bottom number (diastolic).
   • Baseline LVEF below the institutional lower limit of normal or < 50%, whichever is lower.
   • Symptomatic heart failure (as defined by New York Heart Association class ≥ 2).
   • Acute coronary syndrome/acute myocardial infarction, unstable angina pectoris, coronary intervention procedure with percutaneous coronary intervention, or coronary artery bypass grafting within 6 months before C1D1.

6. Prior exposure to any direct small molecule KRAS inhibitor.

7. Herbal preparations/medications are not allowed during treatment with study drug.

8. Any concomitant medications that are known strong inhibitors or inducers of CYP3A4/5, or sensitive CYP3A4/5 substrates or CYP3A4/5 substrates with a narrow therapeutic range. This also applies to moderate inhibitors and moderate inducers of CYP3A4/5 during Parts A and B of Modules 1 and 2.

9. Receipt of a cytotoxic or non-cytotoxic drug: 21 days or 5 half-lives, whichever is shorter, before the first dose of study intervention. Biological therapy including immune-oncology and monoclonal antibodies 28 days or 5 half-lives.

10. Less than or equal to 4 weeks for radiation therapy given with curative intent or ≤ 2 weeks for limited field radiation for palliation prior to the first dose of study treatment

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
For Parts A & B: • Incidence and severity of AEs/SAEs • Incidence of DLTs (Dose Escalation) • Clinically significant changes in vital signs, laboratory parameters, and ECG results • Discontinuation of AZD0022 due to toxicity For Part C: • ORR evaluated according to RECIST v1.1		For Parts A & B: • Incidence and severity of AEs/SAEs • Incidence of DLTs (Dose Escalation) • Clinically significant changes in vital signs, laboratory parameters, and ECG results • Discontinuation of AZD0022 due to toxicity For Part C: • ORR evaluated according to RECIST v1.1

Secondary Outcome Measures

Name	Time	Method
For Parts A&B: • Radiological response evaluated according to RECIST v1.1 (ORR, CR rate, DoR, DCR, DRR, TTR, PFS, and change in tumour size). • OS		For Parts A&B: • Radiological response evaluated according to RECIST v1.1 (ORR, CR rate, DoR, DCR, DRR, TTR, PFS, and change in tumour size). • OS
Continuation of Parts A&B as some translations total more than 500 characters. The proportion of participants demonstrating a complete molecular response upon treatment • Determine plasma, urine, and whole blood concentrations and where appropriate determine PK parameters including, but not limited to Cmax, tmax, AUClast, and t1/2λz after oral administration of AZD0022 and amount excreted in urine.		Continuation of Parts A&B as some translations total more than 500 characters. The proportion of participants demonstrating a complete molecular response upon treatment • Determine plasma, urine, and whole blood concentrations and where appropriate determine PK parameters including, but not limited to Cmax, tmax, AUClast, and t1/2λz after oral administration of AZD0022 and amount excreted in urine.
For Part C: • Incidence of AEs/SAEs • Clinically significant changes in vital signs, laboratory parameters, and ECG results • AZD0022 discontinuation due to toxicity • Radiological response evaluated according to RECIST v1.1 (CR rate, DoR, DCR, DRR, TTR, PFS, and change in tumour size)		For Part C: • Incidence of AEs/SAEs • Clinically significant changes in vital signs, laboratory parameters, and ECG results • AZD0022 discontinuation due to toxicity • Radiological response evaluated according to RECIST v1.1 (CR rate, DoR, DCR, DRR, TTR, PFS, and change in tumour size)
Continuation of Part C as some translation total more than 500 characters • OS • The proportion of participants demonstrating a complete molecular response upon treatment • TDT • TFST		Continuation of Part C as some translation total more than 500 characters • OS • The proportion of participants demonstrating a complete molecular response upon treatment • TDT • TFST

Trial Locations

Locations (1)

Research Site; 🇬🇧 Newcastle upon Tyne, United Kingdom